BİR YÜCEL, K. Et Al. 2023. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.3 , 760-763.

BİR YÜCEL, K., SÜTCÜOĞLU, O., YAZICI, O., YILDIZ, Y., ŞENOL, E., & ÜNER, A., (2023). Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.3, 760-763.

BİR YÜCEL, KADRİYE Et Al. "Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.3, 760-763, 2023

BİR YÜCEL, KADRİYE B. Et Al. "Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.3, pp.760-763, 2023

BİR YÜCEL, K. Et Al. (2023) . "Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.3, pp.760-763.

@article{article, author={KADRİYE BİR YÜCEL Et Al. }, title={Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2023, pages={760-763} }